Analyst Update: Applied Optoelectronics Inc, Ligand Pharmaceuticals Inc., and Momenta Pharmaceuticals, Inc.

Analysts are weighing in on Applied Optoelectronics Inc (NASDAQ:AAOI), Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

Sep 7, 2016 at 3:26 PM
facebook twitter linkedin


Analysts are weighing in on fiber optics expert Applied Optoelectronics Inc (NASDAQ:AAOI), as well as biotech stocks Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Here's a quick roundup of today's brokerage notes on AAOI, LGND, and MNTA.

  • Bullish analyst notes are coming through on AAOI, after the company raised its current-quarter outlook. At least six brokerage firms have raised their price targets on the stock, including Piper Jaffray, which set its mark at $24 -- territory not charted since July 2014. The brokerage firm said it believes the company "is in a position to see impressive growth over the next several quarters." As such, Applied Optoelectronics Inc is up 14.8% at $19.90, and could run higher if short sellers begin to cover. Currently, short interest accounts for one-fourth of the stock's float, or 8.4 times the average pace of trading.
  • LGND is up 5.9% at $114.47, following a price-target increase to $151 from $149 at Roth Capital. Specifically, the brokerage firm said positive mid-stage trial data for Retrophin Inc's (NASDAQ:RTRX) kidney drug, sparsentan -- which LGND holds the rights to -- is "an important win" for both companies. Bullish analyst attention is nothing new for the stock, which boasts four "strong buy" recommendations, versus a single "strong sell." This optimism appears well-deserved, though, since Ligand Pharmaceuticals Inc. sports a roughly 21% year-over-year lead, even after a major pullback last month. 
  • MNTA is sliding after a downgrade to "sell" from "hold" at Maxim. The shares have shed 4% to trade at $11.74, bringing their losses for the year to almost 21%. If Momenta Pharmaceuticals, Inc. continues to struggle on the charts, a round of bearish analyst attention could create additional headwinds. The majority of analysts on Wall Street consider the stock a "strong buy," despite its disappointing performance, without a single "sell" to be found.
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check

Make the Most of the next Expiration Week Countdown!


 




 
Special Offers from Schaeffer's Trading Partners